Publication | Closed Access

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

Esophageal CancerGastrointestinal OncologyMedicineFirst-line CadonilimabGastroenterologyPathologyGastroesophageal Junction AdenocarcinomaCancer TreatmentOncologyRadiation OncologyCancer Research